DE69736068D1 - Faktor viii vom schwein und hybriden - Google Patents

Faktor viii vom schwein und hybriden

Info

Publication number
DE69736068D1
DE69736068D1 DE69736068T DE69736068T DE69736068D1 DE 69736068 D1 DE69736068 D1 DE 69736068D1 DE 69736068 T DE69736068 T DE 69736068T DE 69736068 T DE69736068 T DE 69736068T DE 69736068 D1 DE69736068 D1 DE 69736068D1
Authority
DE
Germany
Prior art keywords
factor viii
pig
hybrid
modified factor
viii proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69736068T
Other languages
English (en)
Other versions
DE69736068T2 (de
Inventor
S Lollar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emory University
Original Assignee
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emory University filed Critical Emory University
Application granted granted Critical
Publication of DE69736068D1 publication Critical patent/DE69736068D1/de
Publication of DE69736068T2 publication Critical patent/DE69736068T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Saccharide Compounds (AREA)
DE69736068T 1996-06-26 1997-06-26 Faktor viii vom schwein und hybride davon Expired - Lifetime DE69736068T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/670,707 US5859204A (en) 1992-04-07 1996-06-26 Modified factor VIII
US670707 1996-06-26
PCT/US1997/011155 WO1997049725A1 (en) 1996-06-26 1997-06-26 Modified factor viii

Publications (2)

Publication Number Publication Date
DE69736068D1 true DE69736068D1 (de) 2006-07-20
DE69736068T2 DE69736068T2 (de) 2006-12-14

Family

ID=24691532

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69736068T Expired - Lifetime DE69736068T2 (de) 1996-06-26 1997-06-26 Faktor viii vom schwein und hybride davon

Country Status (12)

Country Link
US (1) US5859204A (de)
EP (2) EP1561757A1 (de)
JP (2) JP3611860B2 (de)
AT (1) ATE328896T1 (de)
AU (1) AU717686B2 (de)
CA (1) CA2258502C (de)
DE (1) DE69736068T2 (de)
DK (1) DK0939767T3 (de)
ES (1) ES2267146T3 (de)
HK (1) HK1022480A1 (de)
PT (1) PT939767E (de)
WO (1) WO1997049725A1 (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180371B1 (en) * 1996-06-26 2001-01-30 Emory University Modified factor VIII
US7560107B2 (en) * 1996-06-26 2009-07-14 Emory University Modified factor VIII
US6312689B1 (en) 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
US6759216B1 (en) 1998-11-06 2004-07-06 Emory University Glycosylated, low antigenicity low immunogenicity factor VIII
DE59914490D1 (de) * 1998-11-10 2007-10-18 Sanquin Bloedvoorziening Ein faktor viii-polypeptid mit faktor viii:c-aktivität
US6358703B1 (en) 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
WO2000071714A2 (en) 1999-05-24 2000-11-30 The American National Red Cross Methods of reducing factor viii clearance and compositions therefor
CN1205221C (zh) * 2000-09-19 2005-06-08 埃默里大学 修饰的凝血因子ⅷ
US7615622B2 (en) * 2001-01-12 2009-11-10 University Of Maryland, Baltimore Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII
EP1421539B1 (de) 2001-06-14 2009-10-28 The Scripps Research Institute Stabilisierte faktor viii mit gentechnisch konstruierten disulfidbindungen
JP4634036B2 (ja) 2001-10-05 2011-02-16 エクスプレッション セラピューティクス， エルエルシー 高レベルエキスプレッサー第ｖｉｉｉ因子ポリペプチドをコードする核酸配列およびアミノ酸配列および使用方法
WO2003047507A2 (en) * 2001-11-30 2003-06-12 Emory University Factor viii c2 domain variants
US7709224B2 (en) 2003-06-03 2010-05-04 Biosante Pharmaceuticals, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
US7485291B2 (en) 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
WO2005046583A2 (en) * 2003-10-30 2005-05-26 Emory University Modified fviii having reduced immunogenicity through mutagenesis of a2 and c2 epitopes
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
WO2005055930A2 (en) * 2003-12-03 2005-06-23 University Of Rochester Recombinant factor viii having increased specific activity
EP1750733B1 (de) * 2004-05-03 2013-12-11 Emory University Verfahren zur verabreichung von schweine b-domänenlosem fviii
US20060080848A1 (en) * 2004-10-19 2006-04-20 Lace Charles R Wheel blade sight
WO2006063031A2 (en) 2004-12-06 2006-06-15 Haplomics Allelic variants of human factor viii
JP2008534559A (ja) * 2005-04-01 2008-08-28 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 血液凝固ｆｖｉｉｉ類似体
FR2913020B1 (fr) * 2007-02-23 2012-11-23 Biomethodes Nouveaux facteurs viii pour le traitement des hemophiles de type a
AU2008287530A1 (en) * 2007-05-07 2009-02-19 Peptimmune, Inc. Methods for the directed expansion of epitopes for use as antibody ligands
US8338571B2 (en) 2007-11-01 2012-12-25 University Of Rochester Recombinant factor VIII having increased stability
WO2011028229A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor ix compositions and methods of making and using same
HUE036233T2 (hu) 2009-12-06 2018-06-28 Bioverativ Therapeutics Inc VIII-FC Faktor kimérás és hibrid polipeptidek, és ezek használati módszerei
BR112012017483A2 (pt) * 2010-01-14 2019-09-24 Haplomics Inc previsão e redução de aloimunogenicidade de terapêuticos de proteína
WO2011095604A1 (en) 2010-02-04 2011-08-11 Octapharma Biopharmaceuticals Gmbh Half-life prolongation of proteins
JP5826772B2 (ja) * 2010-02-16 2015-12-02 ノヴォ ノルディスク アー／エス コンジュゲートタンパク質
EP2977055A1 (de) * 2010-02-16 2016-01-27 Novo Nordisk A/S Faktor-viii-fusionsproteine
US9611310B2 (en) 2010-07-09 2017-04-04 Bioverativ Therapeutics Inc. Systems for factor VIII processing and methods thereof
US20130017997A1 (en) * 2010-08-19 2013-01-17 Amunix Operating Inc. Factor VIII Compositions and Methods of Making and Using Same
AU2011323236B2 (en) 2010-11-05 2017-03-30 Takeda Pharmaceutical Company Limited A new variant of antihemophilic factor VIII having increased specific activity
AU2012267484B2 (en) 2011-06-10 2017-03-23 Bioverativ Therapeutics Inc. Pro-coagulant compounds and methods of use thereof
PT3513804T (pt) 2011-07-08 2022-06-02 Bioverativ Therapeutics Inc Polipéptidos fator viii híbridos e quiméricos, e métodos de utilização dos mesmos
EP2737311B1 (de) 2011-07-25 2020-12-02 Bioverativ Therapeutics Inc. Tests zur überwachung von blutungsstörungen
EA038705B1 (ru) 2012-01-12 2021-10-07 Биовератив Терапьютикс Инк. Способы снижения иммуногенности фактора свёртывания крови viii у пациентов, получающих лечение фактором viii
PL2804623T3 (pl) 2012-01-12 2020-03-31 Bioverativ Therapeutics Inc. Chimeryczne polipeptydy czynnika viii i ich zastosowania
CA2864904C (en) 2012-02-15 2023-04-25 Amunix Operating Inc. Factor viii compositions and methods of making and using same
EP3549953A1 (de) 2012-02-15 2019-10-09 Bioverativ Therapeutics Inc. Rekombinante faktor-viii-proteine
EP2666782A1 (de) * 2012-05-22 2013-11-27 Imnate Sarl Gerinnungsfaktor VII mit reduzierter Immunogenität
KR102329315B1 (ko) 2012-07-11 2021-11-19 바이오버라티브 테라퓨틱스 인크. Xten 및 폰 빌레브란트 인자 단백질과의 viii 인자 복합체 및 이의 용도
US10001495B2 (en) 2012-07-25 2018-06-19 Bioverativ Therapeutics Inc. Blood factor monitoring assay and uses thereof
CA2888806A1 (en) 2012-10-18 2014-04-24 Biogen Idec Ma Inc. Methods of using a fixed dose of a clotting factor
EP3943102A1 (de) 2012-10-30 2022-01-26 Bioverativ Therapeutics Inc. Verfahren zur verwendung von fviii-polypeptid
WO2014089541A2 (en) 2012-12-07 2014-06-12 Haplomics, Inc. Factor viii mutation repair and tolerance induction
PL3666283T3 (pl) 2013-03-15 2022-10-03 Bioverativ Therapeutics Inc. Formulacje polipeptydu czynnika viii
EP3904376A1 (de) 2013-06-24 2021-11-03 Xiao, Weidong Mutante faktor-viii-zusammensetzungen und verfahren
EP3013358A4 (de) 2013-06-28 2017-03-22 Biogen MA Inc. Durch thrombin spaltbarer linker mit xten und verwendungen davon
WO2015021423A2 (en) 2013-08-08 2015-02-12 Biogen Idec Ma Inc. Purification of chimeric fviii molecules
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
ES2967617T3 (es) 2013-12-06 2024-05-03 Bioverativ Therapeutics Inc Herramientas de farmacocinética poblacional y sus usos
CN106456718A (zh) 2014-01-10 2017-02-22 比奥根Ma公司 因子viii嵌合蛋白及其用途
EP3114138B1 (de) 2014-03-05 2021-11-17 Pfizer Inc. Verbesserte muteine von gerinnungsfaktor viii
WO2017024060A1 (en) 2015-08-03 2017-02-09 Biogen Ma Inc. Factor ix fusion proteins and methods of making and using same
EP3793588A1 (de) 2018-05-18 2021-03-24 Bioverativ Therapeutics Inc. Verfahren zur behandlung von hämophilie a
US11795207B2 (en) 2021-03-30 2023-10-24 AAVnerGene Inc. Modified plasma clotting factor VIII and method of use thereof
WO2022211791A1 (en) 2021-03-30 2022-10-06 AAVnerGene Inc. Modified plasma clotting factor viii and method of use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757006A (en) * 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4965199A (en) * 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US5422260A (en) * 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US5149637A (en) * 1987-04-06 1992-09-22 Scripps Clinic & Research Foundation Recombinant Factor VIIIC fragments
US4980456A (en) * 1987-04-06 1990-12-25 Scripps Clinic And Research Foundation Recombinant factor VIIIC derived fragments
IL86693A (en) * 1987-06-12 1994-06-24 Stichting Centraal Lab Proteins that have the activity IIIV of the blood, a process for their preparation that uses cells are produced through genetic engineering and pharmaceutical preparations that contain them
JPH0387173A (ja) * 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
DK162233C (da) * 1989-11-09 1992-03-16 Novo Nordisk As Fremgangsmaade til isolering af faktor viii fra blodplasma og pharmaceutisk praeparat indeholdende den saaledes isolerede fator viii
US5364771A (en) * 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5663060A (en) * 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US5563045A (en) * 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
AU6291896A (en) * 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs comprising factor v domains or subdomains
WO1997003193A1 (en) * 1995-07-11 1997-01-30 Chiron Corporation Novel factor viii:c polypeptide analogs with altered metal-binding properties

Also Published As

Publication number Publication date
JP3611860B2 (ja) 2005-01-19
WO1997049725A1 (en) 1997-12-31
CA2258502A1 (en) 1997-12-31
US5859204A (en) 1999-01-12
EP0939767B1 (de) 2006-06-07
ATE328896T1 (de) 2006-06-15
ES2267146T3 (es) 2007-03-01
JP3683897B2 (ja) 2005-08-17
EP0939767A1 (de) 1999-09-08
EP0939767A4 (de) 2001-04-04
DE69736068T2 (de) 2006-12-14
EP1561757A1 (de) 2005-08-10
CA2258502C (en) 2003-04-29
AU717686B2 (en) 2000-03-30
PT939767E (pt) 2006-10-31
HK1022480A1 (en) 2000-08-11
JP2000513934A (ja) 2000-10-24
WO1997049725A9 (en) 2005-11-17
AU3643397A (en) 1998-01-14
JP2004141173A (ja) 2004-05-20
DK0939767T3 (da) 2006-10-09

Similar Documents

Publication Publication Date Title
DE69736068D1 (de) Faktor viii vom schwein und hybriden
NO985427L (no) Modulatorer for vevsregenerering
ATE125867T1 (de) Fibronektinbindungsprotein und dessen herstellung.
DE69839444D1 (de) Smad 6 und dessen anwendungen
ITTO950367A0 (it) Proteine di prrsv ricombinanti, corredi diagnostici e vaccini contenenti tali proteine di prrsv ricombinanti.
DE69533564D1 (de) Effektor-Proteine für Rapamycin
DE3585953D1 (de) Dna-fragmente, expressionsvektoren, proteine, wirte und verfahren zur herstellung der proteine.
NO971875D0 (no) Cathepsin 02 protease
NO965123D0 (no) Pantropiske, neurotrofiske faktorer
DE69816689D1 (de) Einrichtung und Methode zur Herstellung von Kraftfahrzeug-stossstangenträgern
DE69823312D1 (de) Produktionssystem zur Herstellung von Luftreifen
DE60023860D1 (de) Verfahren zur herstellung von rekombinanten peptiden
DE69513426D1 (de) Markier-Zusammensetzung, daraus hergestelltes Formteil und Markierungsverfahren
DE69622051T2 (de) Verfahren zur herstellung von 2,4-dihydroxy-pyridin und 2,4-dihydroxy-3-nitropyridin
DK0920501T3 (da) Neuritin, et neurogen
ZA9710163B (en) Novel carboxylesterase nucleic acid molecules, proteins and uses thereof.
DE69725580D1 (de) Prozess zur herstellung von aza zyclohexapeptide
DE69033756T2 (de) Gene, die für MACIF Proteine kodieren, Expressionsvektoren mit diesem Genen, und Transformantenzellen mit diesem Proteinen
MX9806041A (es) Proteina purificada sr-p70.
DE69728897D1 (de) Saeugetierchemokine
PE20399A1 (es) Muteina ob
DE69739071D1 (de) Menschliche tak1 und für diese kodierende dna
ATE283356T1 (de) Tab1 protein und dafür kodierende dna
FR2709132B1 (fr) Fragment d'ADN portant le gène codant pour l'enzyme de fragmentation du N-acétylhéparosane et les séquences adjacentes permettant son expression, enzyme recombinée et son utilisation.
DE69609079D1 (de) Fahrbare einrichtung zur unterhaltung und ausbesserung von gleisanlagen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition